Gamco Investors INC. ET AL Has $11.42 Million Stock Position in HCA Healthcare, Inc. $HCA

Key Points

• Gamco Investors INC. ET AL has reduced its stake in HCA Healthcare by 10.8%, now holding 33,045 shares valued at approximately $11.42 million.
• Several institutional investors, including Price T Rowe Associates Inc. MD and Goldman Sachs Group Inc., increased their holdings significantly in HCA Healthcare, showing strong institutional interest.
• HCA Healthcare recently reported earnings significantly above estimates, with a net margin of 8.21% and projected EPS for FY 2025 set between 25.500-27.000.

Gamco Investors INC. ET AL trimmed its stake in shares of HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 10.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,045 shares of the company's stock after selling 3,989 shares during the quarter. Gamco Investors INC. ET AL's holdings in HCA Healthcare were worth $11,419,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company's stock worth $829,104,000 after acquiring an additional 1,091,416 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of HCA Healthcare by 12.4% in the 4th quarter. Northern Trust Corp now owns 2,017,971 shares of the company's stock worth $605,694,000 after acquiring an additional 223,248 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of HCA Healthcare by 4.5% in the 4th quarter. Nuveen Asset Management LLC now owns 1,865,771 shares of the company's stock worth $560,011,000 after acquiring an additional 81,105 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company's stock worth $615,583,000 after acquiring an additional 587,036 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in HCA Healthcare by 40,527.3% in the 1st quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company's stock worth $5,887,850,000 after purchasing an additional 1,699,713 shares during the last quarter. 62.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HCA shares. JPMorgan Chase & Co. boosted their price objective on shares of HCA Healthcare from $360.00 to $370.00 and gave the stock a "neutral" rating in a research report on Monday, August 4th. Truist Financial boosted their price objective on shares of HCA Healthcare from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. Wolfe Research cut shares of HCA Healthcare from an "outperform" rating to a "peer perform" rating in a research report on Monday, July 28th. Wall Street Zen upgraded shares of HCA Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $444.00 target price on shares of HCA Healthcare in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $401.83.

HCA Healthcare Price Performance

Shares of HCA stock opened at $401.72 on Wednesday. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $417.14. The firm has a market capitalization of $94.00 billion, a price-to-earnings ratio of 16.89, a price-to-earnings-growth ratio of 1.27 and a beta of 1.39. The company has a quick ratio of 0.86, a current ratio of 0.98 and a debt-to-equity ratio of 69.07. The firm has a fifty day moving average of $375.19 and a 200-day moving average of $355.12.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. During the same quarter in the previous year, the business earned $5.50 EPS. The firm's revenue was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, equities research analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, September 16th. This represents a $2.88 annualized dividend and a dividend yield of 0.7%. HCA Healthcare's payout ratio is 12.11%.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.